20966 research outputs found
Sort by
A prospective study of hair dyes and uterine leiomyomata incidence in the study of environment, lifestyle, and fibroids
No full textOBJECTIVE: To investigate associations between hair dye use and incident uterine leiomyomata (fibroids) among Black participants from the Study of Environment, Lifestyle, and Fibroids.
DESIGN: Prospective cohort study.
SUBJECTS: Reproductive-aged (26-39 years) individuals with an intact uterus residing in the Detroit, Michigan area (n = 868).
EXPOSURE: Self-reported hair dye use (any use vs. no use) in the previous 12 months queried on structured questionnaires.
MAIN OUTCOME MEASURES: Fibroid incidence assessed by transvaginal ultrasounds. We fit Cox proportional hazard models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs), adjusting for age, time in study, educational attainment, annual household income, occupational status, body mass index, age at menarche, parity, use of progestin-only injectable contraceptives within the past 2 years, alcohol consumption, and smoking status.
RESULTS: One hundred and forty nine incident fibroid cases were identified over 3,458 person-years of follow-up. After adjustment for confounders, use of any hair dye product (HR = 1.44; 95% CI = 0.91, 2.26) and rinses that fade (HR = 1.98; 95% CI = 1.04, 3.79) in the previous 12 months was associated with increased fibroid risk, compared with no use, although associations were generally imprecise.
CONCLUSION: In this cohort, use of hair dye products was modestly associated with a higher fibroid risk, which has important public health implications
Antiviral treatment Reduces Risk of Development of Lung Cancer and non-Hodgkin Lymphoma in Patients with Chronic Hepatitis C
No full textBACKGROUND: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of HCV patients with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.
METHODS: 17,485 HCV patients were followed until incidence of lung cancer, non-Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations (GEE) with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.
RESULTS: After 15 years of follow-up, we identified 408 incident cases of cancers, including 140 lung, 72 NHL, 81 breast (female), and 115 prostate. Compared to no treatment, patients who receive either direct-acting antivirals (DAA) or interferon-based (IFN) treatment had significantly lower risk of lung cancer (hazard ratio [HR]= 0.35, 95% CI 0.24-0.52 for achieving sustained virological response [SVR]; HR= 0.34, 95% CI 0.21-0.55 for treatment failure). Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancer.
CONCLUSIONS: Antiviral treatment for HCV independently reduced the risk of lung cancer, while the protective association with NHL was limited to patients achieving SVRs.
IMPACT: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV
Beyond the Bedside: How Interdisciplinary Rounds Streamline ICU Care and Transitions
No full texthttps://scholarlycommons.henryford.com/nursresconf2025/1001/thumbnail.jp
Staff Perception of the CPR Coach Role for Codes with Cardiac Arrest in the Emergency Department
No full texthttps://scholarlycommons.henryford.com/nursresconf2025/1005/thumbnail.jp
Decreasing Medical Device-Related Tracheostomy Pressure Injuries with Hydroconductive Dressings
No full texthttps://scholarlycommons.henryford.com/nursresconf2025/1007/thumbnail.jp
Integrating Habilitative Care Team Members in the Neonatal Intensive Care Unit
No full texthttps://scholarlycommons.henryford.com/nursresconf2025/1020/thumbnail.jp
Multi-disciplinary Collaboration on Maintaining Safety Transport for Patients on Supplemental Oxygen
No full texthttps://scholarlycommons.henryford.com/nursresconf2025/1025/thumbnail.jp
Nursing TRUST Program: An Avenue of Support for the Clinical Nurses Who Are Second Victims
No full texthttps://scholarlycommons.henryford.com/nursresconf2025/1040/thumbnail.jp
Enhancing Pulmonary Care in Older Adults: The Vital Role of Healthcare Providers in Managing Age-Related Challenges and Medication Access
No full textThis article explores the use of pulmonary medications in older adults, emphasizing age-related physiologic changes that impact drug efficacy and safety. It discusses common treatments for conditions including bronchodilators, anti-inflammatory therapies, and antifibrotics. The article highlights the importance of individualized dosing due to altered metabolism, increased susceptibility to side effects, and adherence challenges in older adults. Emphasis is also placed on balancing therapeutic benefits with the financial burden associated with the cost of pulmonary medications to improve respiratory function and quality of life in the aging population
Impact of Inhaled Corticosteroids on Osteoporosis in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review
No full textInhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD) management, but their long-term use has been associated with potential adverse effects on bone health, including osteoporosis and fractures. This systematic review aimed to evaluate the impact of ICS on osteoporosis and fracture risk in COPD patients by synthesizing evidence from observational and clinical studies. A comprehensive literature search was conducted across PubMed, Web of Science, Scopus, Embase, and the Cochrane Library, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were screened for eligibility based on predefined inclusion criteria, and data were extracted using a standardized form. The Newcastle-Ottawa Scale (NOS) was employed to assess the risk of bias in included studies. Due to heterogeneity in study designs and outcome measures, a narrative synthesis was performed, focusing on key themes such as dose-response relationships, fracture risk, and the influence of ICS duration. Eleven studies were included, revealing mixed findings on the association between ICS use and bone health outcomes. While some studies reported a dose-dependent increase in osteoporosis incidence and fracture risk, others found no significant association or even protective effects in specific subgroups. High-dose and long-term ICS use were consistently linked to greater risks, particularly in vulnerable populations such as elderly and female patients. The methodological quality of studies varied, with most demonstrating low to moderate risk of bias. This review highlights the complex relationship between ICS use and bone health in COPD patients, emphasizing the importance of individualized treatment approaches. While ICS remain essential for COPD management, clinicians should consider bone-protective strategies in high-risk patients, particularly those on long-term or high-dose regimens. Future research should standardize exposure and outcome definitions to facilitate more robust quantitative synthesis